β-Arrestins are multifunctional proteins identified on the basis of their ability to bind and uncouple G protein-coupled receptors (GPCRs) from heterotrimeric G proteins. In addition, β-arrestins play a central role in mediating GPCR endocytosis, a key regulatory step in receptor desensitization. In this study, we visualize the intracellular trafficking of β-arrestin2 in response to activation of several distinct GPCRs including the β2-adrenergic receptor (β2AR), angiotensin II type 1A receptor (AT1AR), dopamine D1A receptor (D1A), endothelin type A receptor (ETAR), and neurotensin receptor (NTR). Our results reveal that in response to β2AR activation, β-arrestin2 translocation to the plasma membrane shares the same pharmacological profile as described for receptor activation and sequestration, consistent with a role for β-arrestin as the agonist-driven switch initiating receptor endocytosis. Whereas redistributed β-arrestins are confined to the periphery of cells and do not traffic along with activated β2AR, D1A, ETAR, and ETAR in endocytic vesicles, activation of AT1AR and NTR triggers a clear time-dependent redistribution of β-arrestins to intracellular vesicular compartments where they colocalize with internalized receptors. Activation of a chimeric AT1AR with the β2AR carboxyl-terminal tail results in a β-arrestin membrane localization pattern similar to that observed in response to β2AR activation. In contrast, the corresponding chimeric β2AR with the AT1AR carboxyl-terminal tail gains the ability to translocate β-arrestin to intracellular vesicles. These results demonstrate that the cellular trafficking of β-arrestin proteins is differentially regulated by the activation of distinct GPCRs. Furthermore, they suggest that the carboxyl-tail of the receptors might be involved in determining the stability of receptor/β-arrestin complexes and cellular distribution of β-arrestins.

Signal transduction via G protein-coupled receptors (GPCRs) is intimately associated with a wide variety of biological processes including neurotransmission, chemotraction, cardiac function, olfaction, and vision. β-Arrestin proteins play an important role in regulating the responsiveness of GPCRs by contributing to mechanisms involved in both GPCR desensitization and resensitization (1–5). β-Arrestins regulate GPCR desensitization by binding and uncoupling the receptors from heterotrimeric G proteins once they have been phosphorylated by G protein-coupled receptor kinases (GRKs) (1, 3). In addition, they are also required for the sequestration (endocytosis) of a growing number of GPCRs, including the CCR-5, follicitropin receptor, lutropin/choriogonadotropin receptor, m2 muscarinic acetylcholine receptor, mu opioid receptor, substance P receptor, and the β2-adrenergic receptor (β2AR) (4, 6–11). At least in the case of the β2AR, the agonist-dependent sequestration of the receptor to an endosomal compartment not only promotes receptor dephosphorylation but is essential for the re-establishment of normal receptor responsiveness (5, 12–15).

Recent studies suggest that β-arrestins participate in GPCR sequestration by directing receptors to clathrin-coated vesicles (4, 16, 17). β-Arrestins have been shown to undergo redistribution in response to receptor activation both in live cells and following the fixation of cells, and to co-localize with clathrin (7, 11, 18, 19). However, while the phenomenon of β-arrestin cellular trafficking is potentially important for understanding mechanisms underly GPCR internalization and resensitization, the detailed pharmacology of the receptor-mediated β-arrestin redistribution has never been characterized. As a consequence, it is not clear whether the pharmacological profile of β-arrestin translocation recapitulates the pharmacology described for GPCR endocytosis. Moreover, the cellular fate of β-arrestin proteins following association with various GPCRs also remains unknown, as well as where and when β-arrestins dissociate from each receptor. In the case of rhodopsin, it was demonstrated that the interaction of visual arrestin with rhodopsin prevented the dephosphorylation and resensitization of the receptor (20, 21). Therefore, it is likely that the dissociation...
of the β-arrestin/receptor complex contributes to the regulation of responsiveness for other GPCRs.

In the present study, we used a green fluorescent protein conjugate of β-arrestin2 (βarr2-GFP) (18) to examine the cellular trafficking of β-arrestin upon stimulation of several distinct GPCRs. Our data demonstrate that the pharmacology of β-arrestin2 translocation in living cells could account for the agonist dependence of β2AR sequestration. Moreover, β-arrestin2 was observed to redistribute to distinct subcellular locations in response to activation of different GPCRs. This differential redistribution of β-arrestins likely involves the function of the carboxyl-terminal region of the receptors.

**EXPERIMENTAL PROCEDURES**

**Materials**—Human embryonic kidney (HEK 293) cells were provided by the American Type Culture Collection (ATCC). Tissue culture media and fetal bovine serum were obtained from Life Technologies, Inc. Isoproterenol and dopamine were purchased from Research Biochemicals International. Endothelin and neurotensin were from Peninsula Laboratories, and angiotensin II was from Sigma. Rabbit anti-HA polyclonal antibody and mouse anti-HA 12CA5 monoclonal antibody were obtained from Babco and Boehringer Mannheim, respectively. Fluorescein isothiocyanate (FITC)-labeled goat anti-mouse secondary antibody was purchased from Sigma, and rhodamine-conjugated goat anti-rabbit Fabs was obtained commercially from Organon Teknika. [125I]Cyanopindolol was purchased from NEN Life Science Products.

**DNA Construction**—All recombinant DNA procedures were carried out following standard protocols. β-Arrestin1 with GFP conjugated to its COOH terminus (βarr1-GFP) was constructed in a manner similar to βarr2-GFP (18) by replacing the terminal stop codon of β-arrestin1 with a Sall restriction site and inserting the modified cDNA in frame into the polyclinker of pS65TGF-PP-N3 (CLONTECH) (18). pcDNA3-AT1∆R-β2AR-CT and pcDNA1-Amp-β2AR-AT1∆R-CT were constructed by polymerase chain reaction. The chimeric AT1∆R with the β2AR carboxy-terminal tail (AT1∆R-β2AR-CT) contains the first 302 amino acids (Met1–Lys348) of the AT1∆R fused to the last 67 amino acids (CytoLys13) of the β2AR. The chimeric β2AR with the AT1∆R carboxy-terminal tail (β2AR-AT1∆R-CT) includes the first 348 amino acids (Met1–Lys356) of the β2AR fused to the last 38 amino acids (Ala324–Glus259) of the AT1∆R. The sequences of the DNA constructs were confirmed by DNA sequencing.

**Cell Culture and Transfection**—HEK 293 cells were grown in Eagle’s minimum essential medium with Earle’s salt (MEM) supplemented with 10% (v/v) heat-inactivated fetal bovine serum and gentamicin (100 µg/ml). The cells were seeded at a density of 2.5 × 10^6 cells/100-mm dish and transiently transfected with the cDNAs described in the figure legends by a modified calcium phosphate method (22). Following transfection (~18 h), the cells were incubated with fresh medium and allowed to recover 7–9 h before being reseeded into 35-mm glass-bottomed culture dishes (MatTek) or into six-well dishes (Falcon) containing or not containing 22-mm square glass coverslips coated with collagen (Sigma). The use of HEK 293 cells expressing β2AR-GFP was described previously (23).

**Receptor Expression**—β2AR expression was measured by saturating [125I]cyanopindolol binding done at 30 °C for 60 min (24). The expression of other receptors was measured by flow cytometry and normalized according to the β2AR expression measured at the same time by both flow cytometry and saturating binding (16). The receptor expression levels were between 2000 and 4000 fmol/mg of whole cell protein for the experiments assessing β-arrestin translocation with confocal microscopy (see below) and between 1000 and 2000 fmol/mg of whole cell protein for all other experiments.

**Confocal Microscopy**—Confocal microscopy was performed on a Zeiss LSM-410 laser scanning microscope using either Zeiss 40 × 1.3 or Zeiss 63 × 1.4 numerical aperture oil immersion lenses. For characterizing the pharmacology of β-arrestin translocation in living cells, HEK 293 cells expressing β2AR and low levels of βarr2-GFP were plated on 35-mm glass-bottomed culture dishes and kept warm at 30 °C in serum-free MEM on a heated microscope stage. βarr2-GFP fluorescent signals were collected using the Zeiss LSM software time scan function in the photon counting mode using single line excitation (488 nm). Drugs were applied to the cells either prior to or during the scanning of βarr2-GFP labeled cells. For studying β-arrestin trafficking in response to activation of other receptors, HEK 293 cells expressing the receptor of interest and low levels of βarr2-GFP were seeded on 22-mm square glass coverslips, stimulated with saturating concentrations of drugs at 30 °C for 1 h or as indicated, and then fixed with 3.7% paraformaldehyde in phosphate-buffered saline. βarr2-GFP fluorescent signals were collected using single line excitation (488 nm). Colocalization studies of βarr2-GFP and rhodamine-labeled receptor fluorescence were performed using dual excitation (488, 568 nm) and emission (515–540 nm, GFP; 590–610 nm, rhodamine) filter sets. Specificity of labeling and absence of signal cross-over were established by examination of single-labeled samples.

**Immunofluorescent Labeling**—For performing colocalization studies of βarr2-GFP and rhodamine-labeled β2AR in live cells, HER 293 cells expressing HA epitope-tagged β2AR and βarr2-GFP grown on 35-mm glass-bottomed culture dishes were incubated in serum-free MEM containing anti-HA polyclonal antibody at 37 °C for 30 min. Cells were washed three times with ice-cold MEM and incubated for 30 min on ice in the presence of rhodamine-conjugated goat anti-rabbit Fabs. Cells were washed an additional three times with serum-free MEM at 30 °C and imaged by confocal microscopy as described above. For studying colocalization of βarr2-GFP and AT1∆R, HER 293 cells expressing HA epitope-tagged AT1∆R were grown on 22-mm square glass coverslips and incubated in serum-free MEM containing rhodamine-conjugated anti-HA 12CA5 monoclonal antibody on ice for 45 min. Cells were then washed, stimulated with a saturating concentration (500 nM) of angiotensin II for 1 h, washed again, fixed with 3.7% paraformaldehyde in phosphate-buffered saline, and imaged by confocal microscopy as described above.

**Data Analysis**—The changes in βarr2-GFP distribution to the plasma membrane were analyzed with IP Labs software. The magnitude of βarr2-GFP fluorescence at the plasma membrane was determined by integration of the fluorescence signal along the cell perimeter. The relative magnitude of βarr2-GFP distribution along a linear slice of the cell was quantitated by the line scan function provided with the Zeiss LSM 410 image analysis software. βarr2-GFP translocation time course and dose-response curves were analyzed using GraphPad Prism. All data points represent the mean ± S.D.

**RESULTS**

As described previously (18), in the absence of receptor activation βarr2-GFP fluorescence was evenly distributed throughout the cytoplasm and exhibited no apparent enhanced plasma membrane localization (Fig. 1, A and C; control). However, upon agonist-activation of the β2AR, a time-dependent rapid redistribution of βarr2-GFP to the plasma membrane occurred (Fig. 1, A and B). The time course of β-arrestin translocation determined here, t1/2 = 2.3 min (Fig. 1B), followed β2AR phosphorylation (t1/2 = 15–40 s) (24, 25) and preceded β2AR internalization (t1/2 = 10 min) (4). At first βarr2-GFP appeared diffusely at the plasma membrane, but with time a punctate pattern became apparent. Moreover, the redistribution of βarr2-GFP from the cytosol to the plasma membrane was agonist dose-dependent (Fig. 1, C and D). The half-maximal effective concentration (EC50) of agonist was calculated to be 6 nM (Fig. 1D), a value comparable to that reported for β2AR sequestration in HEK 293 cells (11 nM) (26). No significant βarr2-GFP translocation in response to agonist exposure was observed in cells lacking overexpressed β2AR (data not shown). To further test the agonist specificity of βarr2-GFP translocation, cells were treated 5 min with 1 µM isoproterenol to induce βarr2-GFP translocation and then exposed to a saturating concentration of the antagonist propranolol in the presence of the agonist (Fig. 1E). Following the treatment of cells with the antagonist, the distribution of βarr2-GFP fluorescence reversed, with βarr2-GFP redistributing over time from the plasma membrane back to the cytoplasm. However, the redistribution of βarr2-GFP back into the cytoplasm was not immediate, but proceeded over a time course of 5–10 min consistent with previous reports describing agonist-dependent and independent steps of β-arrestin internalization (26). Since the pharmacology of βarr2-GFP translocation accurately reflected the agonist dependence of β2AR sequestration, these results suggest that β-arrestin translocation and receptor binding serve as the agonist-dependent switch triggering endocytosis of the β2AR.

While βarr2-GFP was observed to translocate to the plasma...
membrane and cluster at coated pits (18), βarr2-GFP labeling of 
intracellular endocytic vesicles following β2AR activation was 
never observed. The overall distribution pattern of βarr2-GFP 
appeared different from that of a GFP-conjugated β2AR (23) 
(Fig. 2, A and B). In response to agonist stimulation, the β2AR-
GFP redistributed from a diffuse plasma membrane localiza-
tion to a membrane-associated vesiculated pattern, followed by 
the appearance of β2AR-GFP in endocytic vesicles randomly 
distributed throughout the cytosol of the cell (Fig. 2B). 
Therefore, we examined the agonist-induced intracellular trafficking 
of both the β2AR and βarr2-GFP in the same living cells. To do 
this, β2ARs engineered with an amino-terminal HA epitope tag 
were expressed in HEK 293 cells with βarr2-GFP and labeled 
with 12CA5 monoclonal antibodies, which were themselves 
labeled with rhodamine-conjugated anti-Fabs. β2ARs labeled 
in this manner were still able to respond normally to agonist 
activation (Fig. 2C). In the absence of agonist, β2AR immuno-
fluorescence (red) was localized solely to the plasma mem-
brane, whereas βarr2-GFP fluorescence (green) was limited to 
the cytoplasm (Fig. 2C). In response to agonist activation of 
β2ARs, βarr2-GFP translocated to the receptors at the plasma 
membrane. This was followed by the redistribution of both the 

FIG. 1. Pharmacology and agonist dependence of βarr2-GFP translocation in response to β2AR activation in HEK 293 cells. Visualization (A) and quantitation (B) of the time course for βarr2-GFP membrane translocation in HEK 293 cells expressing β2AR and βarr2-GFP in response to stimulation with 25 μM isoproterenol for 0–15 min. Shown are representative confocal microscopic images of βarr2-GFP fluorescence obtained prior to (control) and 90 s, 3 min, and 10 min following the addition of agonist to the medium. Visualization (C) and quantitation (D) of the agonist dose-dependent membrane translocation of βarr2-GFP in HEK 293 cells in response to 5-min exposures to increasing concentration of isoproterenol 10⁻¹⁰ to 10⁻⁵ M. Shown are representative confocal microscopic images of βarr2-GFP fluorescence in HEK 293 cells obtained prior to (control) and following the addition of 10⁻¹⁰ M, 10⁻⁹ M, and 10⁻⁸ M isoproterenol. (E) Effect of treating cells with the antagonist propranolol on the localization of βarr2-GFP redistributed to the plasma membrane in response to receptor activation. Shown are representative confocal microscopic images of βarr2-GFP fluorescence in HEK 293 cells prior to (control) treatment for 5 min with 1 μM isoproterenol (agonist), following which antagonist (300 μM propranolol) was added to the agonist containing medium to compete for receptor binding sites containing medium and time scanned for an additional 10 min (agonist + antagonist). All cells were transfected with 1 μg of pGFP-N3/βarr2 and 5 μg of 12CA5 epitope-tagged 
β2AR in pcDNA1-Amp, and experiments were performed independently on 4–8 different cells. Experiments were performed on a heated microscope stage set at 30 °C. Data points represent the mean ± S.D. of 8 (B) and 5 (D) different cells from separate transfections. Increased membrane 
localized fluorescence was quantitated using IPLab spectrum image analysis software (Signal Analytics Corp.). The inset bars represent 10 μm.
receptors and β-arrestin to clathrin-coated pits, as denoted by the appearance of yellow hot spots (Fig. 2C). However, while yellow vesicles could be observed close to the membrane surface, no colocalization of βarr$_2$GFP with β$_2$AR-bearing vesicles was ever observed in the cytoplasm of the cell (Fig. 2C). A similar agonist-mediated redistribution of βarr$_1$GFP to plasma membrane-localized β$_2$AR, but not β$_2$AR localized in endocytic vesicles, was also observed (data not shown). These results demonstrate that β$_2$AR/β-arrestin complex dissociates at or close to the plasma membrane, and therefore β-arrestins are excluded from endocytic vesicles shortly following their formation.

In a previous study, we have demonstrated that although the AT$_1$R can utilize a distinct endocytic mechanism, overexpression of exogenous β-arrestins mobilizes the receptor for internalization via clathrin-mediated endocytosis similar to that utilized by the β$_2$AR (16). To further characterize the interaction of β-arrestin with the AT$_1$R, receptor-mediated βarr$_2$GFP trafficking was examined in HEK 293 cells co-expressing the AT$_1$R and βarr$_2$GFP. The cells were stimulated with angiotensin II for various periods of time at 30 °C and observed under confocal microscope. Similar to that observed with the β$_2$AR, βarr$_2$GFP was evenly distributed throughout the cytoplasm in the absence of agonist, but underwent a rapid translocation to the plasma membrane in response to AT1R activation (Fig. 3A). However, activation of the AT$_1$R for a longer period of time (>4 min) resulted in a clear redistribution of βarr$_2$GFP to intracellular endocytic vesicles. βarr$_1$GFP was also observed to undergo a similar redistribution to AT$_1$R-containing endocytic vesicles. With time, the βarr$_2$GFP-containing vesicular structures grew in size and were mobilized to cluster at the perinuclear region of the cells (Fig. 3A). In contrast, under parallel conditions, βarr$_2$GFP remained confined to the plasma membrane even when the β$_2$AR was activated by isoproterenol for 1 h (Fig. 3B). To further confirm that the redistribution of β-arrestins is receptor-driven, we examined the localization of agonist-activated AT$_1$R and βarr$_2$GFP in the same HEK 293 cells. To do this, AT$_1$Rs engineered with an amino-terminal HA epitope tag were expressed in HEK 293 cells with βarr$_2$GFP and labeled with rhodamine-conjugated anti-HA 12CA5 monoclonal antibodies. When the cells were

---

2 R. Oakley, personal communication.
activated by angiotensin II, an agonist-dependent colocaliza-
tion of AT1R red immunofluorescence and βarr2GFP green 
fluorescence was observed and persisted for up to 1 h, as 
reflected by the predominant intracellular yellow vesicular 
structures located at the perinuclear region (Fig. 4). These data 
demonstrate a functional interaction between the AT1R and 
β-arrestin proteins. In addition, our results also indicate that, 
unlike the β2AR/β-arrestin complex, the AT1R/β-arrestin com-
plex remains intact and is mobilized to the interior of the cell 
driven by receptor internalization.

Since the activation of β2AR and AT1R promoted β-arrestin 
trafficking to distinct subcellular locations, we examined the 
redistribution of βarr2GFP in response to activation of several 
other GPCRs to address the generality of the two different 
β-arrestin translocation patterns. To do this, βarr2GFP was co-
expressed in HEK 293 cells with different GPCRs including 
dopamine D1A receptor (D1A), endothelin type A receptor 
(ETα) and neurotensin receptor (NTR). As shown in Fig. 5, in 
response to activation of the D1A and the ETα, βarr2GFP underwent a rapid membrane translocation and remained in a 
punctate pattern at the periphery of the cells for as long as 1 h, 
similar to that observed following β2AR stimulation. In con-
trast, in HEK 293 cells overexpressing the NTR, neurotensin 
stimulation resulted in the redistribution of βarr2GFP fluores-
cence to intracellular vesicular structures with a pattern remin-
iscent of that observed following AT1R activation. There-
fore, different GPCRs either separate from β-arrestins at the 
level of plasma membrane or internalize with β-arrestin in 
intracellular vesicles. This property appears independent of 
both the types of G protein-coupling and agonists.

Previous studies of GPCR internalization have suggested 
that the carboxyl-terminal region is important for receptor 
interaction with β-arrestins (4). Therefore, to examine whether 
the carboxyl-terminal tail of the receptors contributes to the 
differential trafficking of β-arrestin, we engineered chimeric 
mutants of the AT1R and β2AR with their carboxyl-terminal 
region exchanged for that of the other. Like the wild-type 
AT1R and β2AR, the chimeric AT1R and β2AR mutants 
(namely AT1R-β2AR-CT and β2AR-AT1R-CT) underwent 
rapid internalization in response to agonist stimulation (Fig. 
6B). However, when co-expressed with βarr2GFP, angiotensin 
II activation of the AT1R-β2AR-CT did not result in β-arrestin 
trafficking to intracellular vesicles, but rather resulted in a 
β-arrestin membrane localization pattern similar to that ob-
served in response to β2AR activation (Fig. 6A). In fact, 
βarr2GFP fluorescence was retained at the plasma membrane 
for up to 1 h and was never localized to intracellular vesicular 
structures in response to activation of the chimeric AT1R 
mutant. In contrast, the corresponding β2AR chimeric mutant 
with AT1R carboxyl-tail displayed “AT1R-like” phenotype 
and acquired the ability to mediate β-arrestin translocation to 
intracellular vesicles (Fig. 6A). In addition, a β2AR-βarr2GFP 
fusion protein with βarr2GFP attached to the carboxyl termi-

FIG. 3. Differential cellular trafficking of βarr2GFP in response to activation of the AT1R and β2AR. Visualization of the redistribution of βarr2GFP fluorescence with time in response to the activation of the AT1R with 500 nM angiotensin II (A) or the β2AR with 25 μM isoproterenol (B) for 0–60 min. HEK 293 cells were transfected with 1 μg of pGFP-N3/βarr2 and 5 μg of 12CA5 epitope-tagged AT1R or β2AR in 
pcDNA1-Amp. Shown are representative confocal microscopic images of βarr2GFP fluorescence in fixed HEK 293 cells exposed to agonist for the 
times indicated. All experiments were performed at 30 °C on three to five different occasions.
FIG. 4. Colocalization of the AT₁R and βarr₂-GFP following stimulation by angiotensin II. Confocal visualization of the intracellular distribution and colocalization (overlay) of βarr₂-GFP (green) with 12CA5 epitope-tagged AT₁R (red) labeled at 4 °C with rhodamine-conjugated 12CA5 monoclonal antibody in HEK 293 cells. Cells were transfected with 1 μg of pGFP-N3/βarr2 and 5 μg of 12CA5 epitope-tagged AT₁R in pcDNA1-Amp. Shown are representative confocal microscopic images of AT₁R and βarr₂-GFP distribution following AT₁R activation with 500 nM angiotensin II at 30 °C for 1 h. The experiment was performed on two different occasions.

In the present work, we use green fluorescent protein-conjugated β-arrestin2 to study the cellular trafficking of β-arrestin proteins in response to several different GPCRs in both living and fixed cells. By doing so, we show that the pharmacology of β-arrestin translocation underlies the inherent agonist dependence of β₂AR endocytosis. More interestingly, our results demonstrate that the cellular fate of β-arrestin2 (or β-arrestin1) is differentially regulated following activation of distinct GPCRs.

A popular assumption in the field has been that β-arrestins are associated with internalized receptors in intracellular vesicles (reviewed in Refs. 21, 27, and 28). While this appears to be true for some receptors such as the AT₃R and NTR, we found that in the case of the β₂AR, D₁R, and ET AR, β-arrestins do not traffic with the receptors to endosomes and appear to dissociate from receptor-bearing vesicles shortly following their formation. In addition, swapping of the carboxyl-terminal regions between the AT₁R and β₂AR switches the phenotype of both receptors in terms of their ability to mobilize plasma membrane-associated β-arrestin to cytosolic vesicular structures. This indicates that the carboxyl-terminal region of the receptors is important in determining receptor/β-arrestin association and receptor-mediated β-arrestin cellular distribution to the plasma membrane and/or endosomes.

Considerable effort has been expended to uncover receptor endocytic motifs underlying the agonist-dependent endocytosis of GPCRs. The expectation was that discrete amino acid motifs on the GPCRs, similar in function to those utilized by single transmembrane spanning receptors, would be identified (21, 29, 30). However, the matching pharmacology for β-arrestin translocation and β₂AR sequestration described here strongly indicates that β-arrestin binding replaces the exposure of discrete amino acid motifs as the agonist-driven switch regulating receptor endocytosis. In contrast, the agonist dependence of the endocytosis of receptor tyrosine kinases is thought to involve the exposure of tyrosine-containing motifs on the receptors (30–34).

It is likely that the effect of agonist binding to the receptor is to induce an intramolecular rearrangement of multiple intracellular GPCR domains. This results in a generalized receptor conformation that is necessary to promote GRK phosphorylation and β-arrestin binding. Interestingly, this conformational requirement may account for the failure of some opioid agonists to induce the sequestration of the mu opioid receptor and the sequestration defect described for the β₂AR-Y326A mutant (11, 24, 35). Furthermore, experiments using β₂AR/β₂AR chimeric receptors showed that normal sequestration of the resulting chimeras required the swapping of several intracellular domains, including the first and second intracellular loops and the carboxyl tail between the two receptor proteins (36). Thus, it would appear that the endocytic switching function of β-arrestins is related to their role in receptor desensitization, i.e. the binding to and uncoupling of the receptor from its G protein. Once receptors are bound to β-arrestin, they then gain the ability to traffic to clathrin-coated pits. Indeed, photobleaching experiments of β₂AR-GFP in HEK 293 cells suggest that desensitized receptors (i.e. complexed with β-arrestins) are free moving in the plasma membrane and that their movement to coated pits is not rate-limiting for β₂AR endocytosis (23). This suggests that the interaction of β-arrestin with the β₂AR represents the initiating event for receptor endocytosis.
Whereas there is growing evidence supporting β-arrestins as a general endocytic intermediate for many GPCRs, it is somewhat surprising that β-arrestins do not traffic to the same cellular compartments upon activation of distinct receptors. The internalization of β-arrestin with some GPCRs but not with others suggests that the properties of β-arrestin/receptor interactions differ for different GPCRs. For example, in the case of the α2-adrenergic receptor, β-arrestins were demonstrated to bind to the third intracellular loop, whereas β-arrestin interactions with the β2AR appear to involve multiple receptor domains including the receptor carboxyl terminus (36, 37). In addition, peptide inhibition studies suggest that the third and, to a lesser extent, the first intracellular loops of rhodopsin may play an important role in arrestin binding to light-activated forms of rhodopsin (38). In the present study, these differences are highlighted by the ability of β-arrestin2 to internalize with the AT1AR and NTR, but not the β2AR, D1AR, and ET2AR. In the case of the AT1AR, it appears that the carboxy-terminal tail contributes directly to β-arrestin interactions. While it is plausible that these differences are the consequence of the high affinity and slow off-rate of peptide ligands that might trap receptors in a conformation favoring stable β-arrestin binding, the observation that the ET2AR do not internalize with β-arrestin bound does not support this apparently simple explanation. Rather, the present experiments with an AT1AR-β2AR carboxy-terminal tail chimera as well as a β2AR-AT1AR carboxy-terminal tail chimera suggest that these differences appear to be regulated by differences in either the tertiary structure or β-arrestin-interacting sequences in the carboxy-terminal domains of these receptors. Presumably, the carboxy-terminal domain in conjunction with other intracellular receptor domains determines the relative stability of receptor/β-arrestin complexes.

In a previous study, we have reported that, although the AT1AR is capable of utilizing a dynamin- and β-arrestin-independent endocytic pathway, co-expression of β-arrestins significantly increases the level of dynamin-dependent AT1AR internalization (16). This suggests that the AT1AR has the ability to directly interact with β-arrestins. In this study, using the GFP-conjugated β-arrestin2, we were able to visualize an agonist-dependent co-trafficking of the receptor with β-arrestins to endocytic vesicles. This represents the first direct demonstration of AT1AR association with β-arrestins. As GRKs were shown to phosphorylate and desensitize the AT1AR (39), it is probable that, similar to their role in βAR function, β-arrestins also play an important role in AT1AR regulation by binding to the GRK-phosphorylated form of the receptor. In addition to the AT1AR and β2AR, we also visualized the trafficking of several other receptors with β-arrestins, including the D1R, ET2R, and NTR. The activation of the NTR resulted in an “AT1AR-like” β-arrestin distribution pattern, whereas the activation of the other two receptors triggered a membrane localization of β-arrestins similar to that observed for the β2AR. These observations indicate that, while GPCR/arrestin interactions represent a general GPCR regulatory mechanism, the stability of receptor/β-arrestin complexes differs from receptor to receptor.

The binding of arrestin proteins to GRK-phosphorylated GPCRs serves to desensitize various GPCRs, following which, the agonist-promoted receptor internalization is proposed to contribute to receptor dephosphorylation and resensitization (21, 40). A critical step leading to effective GPCR dephosphorylation and resensitization is the dissociation of the GPCR/arrestin complex, since dephosphorylation of rhodopsin was demonstrated to be blocked when the receptor is arrestin-bound (20). Our results indicate that β-arrestins dissociate from the β2AR shortly following the redistribution of β-arrestins to coated pits. This early dissociation of GPCR/β-arrestin complexes is presumably appropriate to allow the β2AR to associate with receptor phosphatase and dephosphorylate in...
early endosomes (15). On the other hand, for GPCRs that internalize with β-arrestins bound, it might be expected that the kinetics of dephosphorylation of these receptors would be slower. While β-arrestin binding to receptors may be a general feature of GPCR regulation, our results suggest that the nature of this association or the stability of receptor/β-arrestin complex differs depending upon the receptor studied. Therefore, studies on the dissociation of receptor/β-arrestin complex should be valuable for understanding the mechanisms by which receptor desensitization and resensitization are achieved. The development of mutant or chimeric receptors with altered ability to interact with β-arrestins should greatly facilitate this goal.

Acknowledgment—We thank Sobha Budduluri for expert technical assistance.

REFERENCES
1. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1996) Science 271, 1547–1550
2. Pippig, S., Andexinger, S., Daniel, K., Puzicha, M., Caron, M. G., Lefkowitz, R. J., and Lohse, M. J. (1993) J. Biol. Chem. 268, 3201–3208
3. Attiramadal, H., Arriza, J. L., Aoki, C., Dawson, T. M., Codina, J., Kwatra, M. M., Snyder, S. H., Caron, M. G., and Lefkowitz, R. J. (1992) J. Biol. Chem. 267, 17882–17890
4. Ferguson, S. S., Downey, W. E., III, Colapinto, A. M., Barak, L. S., Menard, L., and Caron, M. G. (1996) Science 271, 363–366
5. Zhang, J., Barak, L. S., Winkler, K. E., Caron, M. G., and Ferguson, S. S. (1997) J. Biol. Chem. 272, 27005–27014
6. Lazari, M. F., Bertrand, J. E., Nakamura, K., Liu, X., Krupnick, J. G., Benovic, J. L., and Ascoli, M. (1998) J. Biol. Chem. 273, 18316–18324
7. McConalogue, K., Corvera, C. U., Gamp, P. D., Grady, E. F., and Bunnett, N. W. (1998) Mol. Biol. Cell 9, 2305–2324
8. Nakamura, K., Krupnick, J. G., Benovic, J. L., and Ascoli, M. (1998) J. Biol. Chem. 273, 24346–24354
9. Aramori, I., Ferguson, S. S. G., Bieniasz, P. D., Zhang, J., Cullen, B., and Caron, M. G. (1997) EMBO J. 16, 4606–4616
10. Schlader, M. L., and Nathans, N. M. (1997) J. Biol. Chem. 272, 18882–18890
11. Zhang, J., Ferguson, S. S., Barak, L. S., Bodulduiri, S. R., Laporte, S. A., Law, P. Y., and Caron, M. G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7157–7162
12. SiIley, D. R., Strasser, R. H., Benovic, J. L., Daniel, K., and Lefkowitz, R. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 9408–9412
13. Yu, S. S., Lefkowitz, R. J., and Hausdorff, W. P. (1993) J. Biol. Chem. 268, 337–341
14. Pippig, S., Andexinger, S., and Lohse, M. J. (1995) Mol. Pharmacol. 47, 666–676
15. Kraeger, K. M., Daaka, Y., Pitcher, J. A., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 5–8
16. Zhang, J., Ferguson, S. S. G., Barak, L. S., Menard, L., and Caron, M. G. (1996) J. Biol. Chem. 271, 18302–18305
17. von Zastrow, M., and Kohlika, B. K. (1992) J. Biol. Chem. 267, 3530–3538
18. Barak, L. S., Ferguson, S. S., Zhang, J., and Caron, M. G. (1997) J. Biol. Chem. 272, 27497–27500
19. Goodman, G. B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, B. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447–450
20. Palczewski, K., McDowell, J. H., Jakes, S., Ingelbritsen, T. S., and Hargrave, P. A. (1989) J. Biol. Chem. 264, 15770–15773
21. Ferguson, S. S., Barak, L. S., Zhang, J., and Caron, M. G. (1996) Can. J. Physiol. Pharmacol. 74, 1095–1110
22. Cullen, B. R. (1987) Methods Enzymol. 152, 684–704
23. Barak, L. S., Ferguson, S. S., Zhang, J., Martenson, C., Meyer, T., and Caron, M. G. (1997) Mol. Pharmacol. 51, 177–184
24. Ferguson, S. S., Menard, L., Barak, L. S., Koch, W. J., Colapietro, A. M., and Caron, M. G. (1995) J. Biol. Chem. 270, 24782–24789
25. Roth, N. S., Campbell, P. T., Caron, M. G., Lefkowitz, R. J., and Lohse, M. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6201–6204
26. von Zastrow, M., and Kohlika, B. K. (1994) J. Biol. Chem. 269, 18448–18452
27. Carman, C. V., and Benovic, J. L. (1998) Curr. Opin. Neurobiol. 8, 335–344
28. Krupnick, J. G., and Benovic, J. L. (1998) Annu. Rev. Pharmacol. Toxicol. 38, 289–319
29. Bohm, S. K., Grady, E. F., and Bunnett, N. W. (1997) Biochem. J. 322, 1–18
30. Trowbridge, I. S., Collawn, J. F., and Hopkins, C. R. (1999) Annu. Rev. Cell Biol. 9, 129–161
31. Chang, M. P., Mallet, W. G., Mostov, K. E., and Brodsky, F. M. (1993) EMBO J. 12, 2169–2180
32. Bansal, A., and Gierasch, L. M. (1991) Cell 67, 1195–1201
33. Eberle, W., Sander, C., Klaus, W., Schmidt, B., von Figura, K., and Peters, C. (1991) Cell 67, 1203–1209
34. Ohno, H., Stewart, J., Fournier, M. C., Boashart, H., Rhee, I., Miyatake, S., Saito, T., Gallusser, A., Kirchhausen, T., and Bonifacino, J. S. (1995) Science 269, 1872–1875
35. Barak, L. S., Menard, L., Ferguson, S. S., Colapietro, A. M., and Caron, M. G. (1995) Biochemistry 34, 15407–15414
36. Jockers, R., Da Silva, A., Strosberg, A. D., Bouvier, M., and Marullo, S. (1996) J. Biol. Chem. 271, 9355–9362
37. Wu, G., Krupnick, J. G., Benovic, J. L., and Lanier, S. M. (1997) J. Biol. Chem. 272, 17836–17842
38. Krupnick, J. G., Gurevich, V. V., Schepers, T., Hamm, H. E., and Benovic, J. L. (1994) J. Biol. Chem. 269, 3226–3232
39. Oppermann, M., Freedman, N. J., Alexander, R. W., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13266–13272
40. Zhang, J., Ferguson, S. S., Barak, L. S., Jaber, M., Giros, B., Lefkowitz, R. J., and Caron, M. G. (1997) Receptors Channels 5, 193–199